BLFS — Q2 2026 Financial Report Analysis

CryoStor demand drove 21% growth; a one-off tax gain made up nearly all of net income

BioLife Solutions makes the liquids and containers that keep living cells alive while they are frozen, stored and shipped. Its main customers are companies making cell and gene therapies (CGT), treatments built from a patient's own or donor cells. In the quarter to June 30, 2026, revenue rose 21% to $28.5 million. The 10-Q says the increase was "largely driven by an increase in customer demand for our biopreservation media products." The headline net income of $45.1 million (diluted EPS of $0.91) is misleading. $42.4 million of it was a non-cash accounting gain on taxes, explained below. The business itself earned $1.7 million of operating income.

This was also BioLife's last quarter as a public company. On July 21, 2026 it agreed to be acquired by Repligen for $11.25 in cash plus 0.1442 Repligen shares per BioLife share. The company valued the deal at about $1.5 billion of enterprise value. The deal closed on October 6, 2026 and the stock was delisted from Nasdaq.

At a glance

• Revenue of $28.5M, up 21% (+$5.0M): growth came from the core media franchise. CryoStor, BioLife's cell-freezing solution, made up 84% of revenue, up from 80% a year ago.
• Operating income of $1.7M against a $16.1M loss a year ago: most of the swing is a $15.5M one-time charge in Q2 2025. Without that charge, the year-ago operating loss was about $0.6M. The real improvement is about $2.3M.
• Net income of $45.1M, of which $42.4M was a one-time tax benefit: the company says this benefit added $0.87 to EPS. That leaves underlying EPS of only about $0.04 to $0.05 a share.

Key figures

n/m = not meaningful, because the year-ago figure was a loss. Net income and EPS include discontinued operations; that line was zero in 2026 and -$0.5M (-$0.01 a share) in Q2 2025.

What drove revenue

BioLife now reports as a single business. Its last non-core unit, the SAVSU/evo smart shipping-container business, was sold in October 2025 and is excluded from all figures as a discontinued operation. What remains is mostly biopreservation media: CryoStor freezing solution and HypoThermosol cold-storage solution. Smaller lines include cell-culture supplements (hPL), CellSeal vials, cell-filling machines and ThawSTAR thawing devices.

• CryoStor did the work. It was 84% of Q2 revenue, about $23.9M, against 80% (about $18.8M) a year earlier, based on the 10-Q's rounded percentages. That is roughly 27% growth for the product, so the rest of the portfolio grew much more slowly.
• Sales outside the U.S. grew faster. Europe, Middle East and Africa rose from 7% of revenue to 13%, which is roughly $1.6M to $3.7M. The U.S. share fell from 88% to 81%.
• The company's customer base is entrenched. The earnings release says its media is used in about 250 commercially sponsored U.S. clinical trials. It claims a share above 70% of those trials and nearly 80% of Phase III trials, the final stage before approval. The media is also embedded in 18 approved therapies, with approvals for 8 more products, new indications or new countries expected over the next 12 months. A therapy's approved manufacturing process is hard to change once a preservation medium is written into it, so each approval tends to bring repeat orders for years.
• Sequential growth was modest. Revenue was $28.5M against $27.5M in Q1 2026, up 4%.

Margins: slightly thinner per sale, but overheads grew slower than revenue

Gross margin is the share of revenue left after the direct cost of making the product. It slipped from 65.0% to 64.2%. Management attributes this to "a less favorable product mix", meaning a larger share of sales came from lower-margin products. That is a little odd in a quarter when the high-margin CryoStor line gained share. The filing does not break it down further.

Operating expenses were $16.6M against $31.4M. Almost all of that drop is the absence of the $15.5M in-process R&D charge from Q2 2025, which was the purchase price of PanTHERA's freezing technology, written off immediately because it was still under development. Excluding that charge:

• G&A (general and administrative) fell 5% to $10.7M. Stock-based pay was lower, partly offset by $0.8M of deal costs. G&A still takes 38% of revenue, which is heavy for a company this size.
• R&D rose 51% to $3.0M from higher testing costs and more staff.
• Sales and marketing rose 8% to $2.8M.

Operating margin, the share of revenue left after running the business before interest and tax, came to 6.0%. In Q1 it was about 0.1%, with operating income of roughly $0.03M.

What the headline numbers hide

• The $42.4M tax benefit is an accounting entry, not cash. For years BioLife carried a "valuation allowance", an accounting reserve that says past tax losses probably can't be used against future profits. In Q2 the company concluded that, given "sustained profitability in recent years" and expected future earnings, those losses will likely be usable. It released $42.4M of that reserve. The release booked a $42.2M deferred tax asset on the balance sheet. No cash came in. Excluding the benefit, pre-tax income was $2.8M, and the company's own adjusted net income was $4.2M.
• The GAAP-to-adjusted gap is large. Adjusted EBITDA (earnings before interest, tax, depreciation and amortization, also excluding certain costs) was $7.4M against GAAP operating income of $1.7M. The difference is mostly $3.9M of stock-based pay, plus $0.8M of deal costs, $0.2M of severance and $0.8M of depreciation and amortization. Stock-based pay is a real cost to shareholders, paid in diluted ownership rather than cash. Treating 26% as BioLife's true margin overstates it.
• Cash flow lagged. Operating cash flow for the first half was $5.9M, down from $9.1M a year earlier, even though revenue grew 23%. Net income excluding the non-cash tax benefit was roughly $3.9M, so cash still exceeded underlying earnings. The decline comes from working capital, the cash tied up in inventory and unpaid customer bills. Inventory rose $5.4M (18%) to $35.6M in six months. Receivables rose 34% to $10.7M. Both grew faster than sales. The 10-Q calls this "timing of collection and disbursement."
• Customer concentration is high and rising. One customer, "Customer D" in the filing, provided 21% of Q2 revenue, up from 18% a year earlier. It also accounted for 36% of receivables at June 30, against under 10% at year-end. Two other customers made up 14% and 12% of revenue. On the supply side, one supplier provided 20% of Q2 purchases, against no supplier above 10% a year earlier.
• Cash fell because of the debt payoff and employee taxes, not losses. Cash and investments fell from $120.2M to $113.1M. The company repaid the last $5.0M of its term loan, which matured on June 1. It also spent $6.7M paying employees' withholding taxes on vesting shares in cash, instead of having employees sell shares to cover them. Debt is now zero.

Takeaway: Underneath a $45.1M headline profit, BioLife earned about $1.7M from operations on $28.5M of revenue. Repligen paid about $1.5 billion of enterprise value, roughly 13 times BioLife's first-half revenue run rate. That price reflects how hard CryoStor is to displace once it is written into an approved therapy, not current earnings.

Looking ahead

There is no guidance to measure against. BioLife did not hold an earnings call or give a forecast "due to the pending acquisition." The merger closed on October 6, 2026. Each BioLife share converted into $11.25 in cash plus 0.1442 Repligen shares. BioLife is now a wholly owned Repligen subsidiary and will no longer publish its own results. This is our first report on BioLife and very likely the last standalone one, so there is no earlier outlook to check against.

Former shareholders now hold Repligen stock, and BioLife's results will appear inside Repligen's reports. Three things in this quarter are worth watching there:

1. Whether the therapy pipeline turns into revenue. The company expects 8 more approvals, expansions or new indications in the next 12 months on top of its 18 approved therapies. Each one adds recurring media demand, and that underpins the price Repligen paid.
2. Customer concentration. With one customer at 21% of revenue and 36% of receivables, a change in a single therapy's sales or production schedule would move BioLife's numbers. The filing does not name the customer.
3. Whether the inventory build unwinds. Inventory rose 18% in six months while revenue grew 23% year on year, after the switch to weighted-average costing in Q1. If that inventory sells, cash conversion should improve. If it does not, gross margin would come under pressure.

At a 64% gross margin and only a 6% operating margin, the gap is mostly corporate overhead, at 38% of revenue in G&A. That is the cost a larger owner like Repligen is best placed to cut. BioLife was profitable before the tax benefit, but the profit was small. The deal price only makes sense if BioLife's revenue can be run with much lower overhead.